*Refresh the page if the below document does not appear.
Cipla, JB Chemicals, and Torrent leading Rs 4,500-crore race for Medley Pharma
Cipla, KKR-owned JB Chemicals, and Torrent Pharmaceuticals NSE 0.06% are competing for the right to buy Medley Pharmaceuticals in a deal estimated to be worth $4,500 crore.
CDSCO Panel Orders Sun Pharma to Conduct Phase III for Psoriasis Drug Tildrakizumab
Subject Expert Committee under the control of CDSCO has recommended Sun Pharma, a major pharmaceutical company, to conduct a Phase III bridging clinical trial with at least 100 patients, 5% of whom should have psoriasis with tuberculosis.
India seeks drug market access in South America
In the $58 billion South American market, India is pushing for preferential market access for pharmaceutical products like generics, active pharmaceutical ingredients (APIs), and alternative medicines.
India MD: GSK's pharmaceutical brands doing well
GlaxoSmithKline Pharmaceuticals said its top medicine brands, including Augmentin, Calpol, and Supacef, are maintaining market share, and that the recent price increase and partial stabilisation of raw material prices will help it maintain operating margins in FY23.
As per AWACS, Indian pharmaceutical market grew 12.1% in August
According to market research company AWACS, the Indian pharmaceutical market (IPM) expanded strongly across all therapy areas in August, growing 12.1% in value and 4.8% in volume.
Azurity Pharma's Konvomep approved by USFDA to treat active benign gastric ulcers
USFDA has approved Konvomep, according to Azurity Pharmaceuticals, Inc., a pharmaceutical company dedicated to creating novel dose-forms and product formulations to meet the needs of underserved patients.
USFDA approves SPEVIGO to combat flare-ups of generalised pustular psoriasis
SPEVIGO, the first approved treatment option
for generalised pustular psoriasis (GPP) flares
in adults, has been approved by the U.S. Food
and Drug Administration (USFDA), according
to a statement from Boehringer Ingelheim.
